311 related articles for article (PubMed ID: 35812369)
21. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
[TBL] [Abstract][Full Text] [Related]
22. Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
Wang T; Ding G; Wang X; Cui Y; Ma X; Ma J; Wu J
Arch Med Res; 2024 Jan; 55(1):102927. PubMed ID: 38154234
[TBL] [Abstract][Full Text] [Related]
23. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
24. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
[No Abstract] [Full Text] [Related]
25. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
26. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
Mi Y; Wang X
J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
[TBL] [Abstract][Full Text] [Related]
28. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
Front Genet; 2021; 12():551605. PubMed ID: 33732281
[No Abstract] [Full Text] [Related]
29. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Chen H; Yang W; Ji Z
Front Immunol; 2023; 14():1171420. PubMed ID: 37063886
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
Song Q; Zhou Z; Bai J; Liu N
Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
Li H; Zhang Y; Zheng S
Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
Song Q; Zhou R; Shu F; Fu W
Front Immunol; 2022; 13():958368. PubMed ID: 35990642
[TBL] [Abstract][Full Text] [Related]
34. Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors.
Cai Y; Ji W; Sun C; Xu R; Chen X; Deng Y; Pan J; Yang J; Zhu H; Mei J
Front Immunol; 2021; 12():704965. PubMed ID: 34456915
[TBL] [Abstract][Full Text] [Related]
35. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
Front Oncol; 2021; 11():636870. PubMed ID: 33747959
[TBL] [Abstract][Full Text] [Related]
36. Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer.
Yao Z; Zhang H; Zhang X; Zhang Z; Jie J; Xie K; Li F; Tan W
Front Genet; 2022; 13():923768. PubMed ID: 36147509
[TBL] [Abstract][Full Text] [Related]
37. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
[TBL] [Abstract][Full Text] [Related]
38. Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
Chen S; Ran J; Fan Z; Liu M; Wu L; Li Q; Peng J; Hu Z
Sci Rep; 2023 Aug; 13(1):12625. PubMed ID: 37537337
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.
Li Y; Fu L; Wu B; Guo X; Shi Y; Lv C; Yu Y; Zhang Y; Liang Z; Zhong C; Han S; Xu F; Tian Y
Cancer Cell Int; 2023 Sep; 23(1):189. PubMed ID: 37660019
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression.
Du Y; Cao J; Jiang X; Cai X; Wang B; Wang Y; Wang X; Xue B
Cancer Cell Int; 2021 Nov; 21(1):613. PubMed ID: 34801033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]